Merck On Track To File Novel Sleep Aid Suvorexant In 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.